Abstract:BRCA 1/2 genes mutation status can already determine the therapeutic algorithm of high grade serous ovarian cancer patients. Nevertheless, its assessment is not sufficient to identify all patients with genomic instability, since BRCA 1/2 mutations are only the most well-known mechanisms of homologous recombination deficiency (HR-d) pathway, and patients displaying HR-d behave similarly to BRCA mutated patients. HRd assessment can be challenging and is progressively overcoming BRCA testing not only for prognostic information but more importantly for drugs prescriptions. However, HR testing is not already integrated in clinical practice, it is quite expensive and it is not refundable in many countries. Selecting patients who are more likely to benefit from this assessment (BRCA 1/2 WT patients) at an early stage of the diagnostic process, would allow an optimization of genomic profiling resources. In this study, we sought to explore whether somatic BRCA1/2 genes status can be predicted using computational pathology from standard hematoxylin and eosin histology. In detail, we adopted a publicly available, deep-learning-based weakly supervised method that uses attention-based learning to automatically identify sub regions of high diagnostic value to accurately classify the whole slide (CLAM). The same model was also tested for progression free survival (PFS) prediction. The model was tested on a cohort of 664 (training set: n = 464, testing set: n = 132) ovarian cancer patients, of whom 233 (35.1%) had a somatic BRCA 1/2 mutation. An area under the curve of 0.7 and 0.55 was achieved in the training and testing set respectively. The model was then further refined by manually identifying areas of interest in half of the cases. 198 images were used for training (126/72) and 87 images for validation (55/32). The model reached a zero classification error on the training set, but the performance was 0.59 in terms of validation ROC AUC, with a 0.57 validation accuracy. Finally, when applied to predict PFS, the model achieved an AUC of 0.71, with a negative predictive value of 0.69, and a positive predictive value of 0.75. Based on these analyses, we have planned further steps of development such as proving a reference classification performance, exploring the hyperparameters space for training optimization, eventually tweaking the learning algorithms and the neural networks architecture for better suiting this specific task. These actions may allow the model to improve performances for all the considered outcomes.

Using deep learning for predicting the dynamic evolution of breast cancer migration

Deep Learning for Predicting Metastasis on Melanoma WSIs

Inference of weak-form partial differential equations describing migration and proliferation mechanisms in wound healing experiments on cancer cells

Deep Learning-based Prediction of Breast Cancer Tumor and Immune Phenotypes from Histopathology

Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology

Deep Learning Method to Predict Wound Healing Progress Based on Collagen Fibers in Wound Tissue

Automated chronic wounds medical assessment and tracking framework based on deep learning

MetaCancer: A deep learning-based pan-cancer metastasis prediction model developed using multi-omics data

Predicting the Progression of Cancerous Tumors in Mice: A Machine and Deep Learning Intuition

Partial differential equation-based inference of migration and proliferation mechanisms in cancer cell populations

Computational Pathology for Accurate Prediction of Breast Cancer Recurrence: Development and Validation of a Deep Learning-based Tool

Development and validation of an artificial intelligence model for predicting de novo distant bone metastasis in breast cancer: a dual-center study

Automated Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy from DWI Data

A novel pipeline employing deep multi-attention channels network for the autonomous detection of metastasizing cells through fluorescence microscopy

Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer

Single clonal tracking on biomimetic microtextured platforms for real-time guided migration analysis of myeloid-derived suppressor cell dissemination characteristics ex vivo

Designing a Deep Learning-Driven Resource-Efficient Diagnostic System for Metastatic Breast Cancer: Reducing Long Delays of Clinical Diagnosis and Improving Patient Survival in Developing Countries

A digital pathology AI model to predict immune-oncology biomarker status and pembrolizumab response in a real-world cohort of patients with colorectal and breast cancer.

Prediction and Related Genes of Cancer Distant Metastasis Based on Deep Learning.

Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer